Here’s what you should know:
1. Neither party disclosed terms of the sale, but Armune CEO David Esposito said the sale “was a really good, solid deal for the company.”
2. Armune sold to Exact Sciences because of Exact’s parallel cancer diagnostic test Cologuard.
3. Mr. Esposito said, “Given Exact’s resources and their scientific expertise, we couldn’t think of a better home for the technology. It’s a great fit for our technology, and we think it has a real strong chance at really impacting the early detection of cancer combined with them.”
4. The sale closed in mid-December 2017 but was not publicly announced until January.
5. Exact CEO Kevin Conroy said Armune is in line with the company’s goal of developing diagnostic tests for the 10 most prevalent U.S.-based cancers.
More articles on gastroenterology:
14 statistics on GI physician salary, compensation
Pennsylvania hospital to acquire Central Penn Gastroenterology Associates — 3 things to know
Johns Hopkins develops blood test for 8 cancers, 5 of which have no screening option
